For Research & Educational Discussion Only. Not Medical Advice
Every guide opens onto its own forum
43 compounds, each with its own forum and the literature sitting beside it. Every post says whether it is anecdote or cited research, and every removal leaves a public reason and the rule it cited.
The guides
Every guide states its evidence level on a five point ladder and its legal status up front, so something with three phase III trials never looks the same as something with one mouse study. Open to read with a free account.
GLP-1 receptor agonist
GLP-1 receptor agonist, Ozempic, Wegovy
A long-acting GLP-1 receptor agonist with large phase III programmes in type 2 diabetes, obesity, and cardiovascular outcomes. One of the few entries here where the evidence base is genuinely deep.
Dual GIP and GLP-1 receptor agonist
GIP/GLP-1 dual agonist, Mounjaro, Zepbound
A dual incretin agonist hitting both GIP and GLP-1 receptors. Phase III results in diabetes and obesity are larger than single-agonist comparators; the mechanistic reason is still argued.
Synthetic pentadecapeptide (gastric peptide fragment)
Body Protection Compound 157, PL 14736, Pentadecapeptide BPC 157
A 15-amino-acid sequence with a large, remarkably consistent animal literature, almost all of it from a small affiliated research network, and no completed human trial reporting results.
Copper-binding tripeptide
Copper peptide, Glycyl-L-histidyl-L-lysine copper
A copper-binding tripeptide with extensive in vitro data and modest topical cosmetic evidence. The gap between the gene-expression literature and what topical application does is very wide.
Dual glucagon and GLP-1 receptor agonist
BI 456906, BI456906
A dual glucagon/GLP-1 agonist in phase 3 for obesity and for MASH. Real trials, real sponsor, no approval anywhere yet, and the phase 3 readouts that matter are not published.
Nonapeptide hormone (posterior pituitary)
Pitocin, Syntocinon
An approved obstetric drug with a very large literature, and a second life as a social and behavioural intervention where the evidence is far weaker than the popular account of it.
Currently on the table
Hand-picked threads worth your reply, not an algorithm's guess. Titles and evidence labels are public; the bodies open with membership.
From the guide: Tirzepatide engages both incretin receptors, with a binding profile that is…
Members only. Join to read the rest
The regimen, as recorded on the guide from the paper's own abstract: Dose: 2.4, 4.8 or 6.0 m…
Members only. Join to read the rest
Starting this category with the least popular part of the most popular compound. From the gu…
Members only. Join to read the rest
Sermorelin is a Growth hormone releasing hormone (GHRH) analogue. Its regulatory posture in…
Members only. Join to read the rest
This is the cleanest example on the site of why a trial count on its own is worthless. Human…
Members only. Join to read the rest
How discussion is organised
The same six run through every guide, so a BPC-157 experience log and a semaglutide literature review sit in the same shape of room. Category choice sets the standard of evidence, and the rules say so.
Papers, preprints, and the arguments about what they actually show.
41Mechanism, pharmacokinetics, stability, and analytical chemistry.
2First-person reports, labelled honestly as n=1.
1Study designs, trial protocols, and how research is structured.elevated safety rules
3Risk, adverse events, contraindications, and knowing when to stop.elevated safety rules
2Regulation, industry, meta-discussion, and everything else.
1Study summaries
Written by members, reviewed before featuring, and deliberately boring about what the evidence does and does not show.
A review of autoradiography and single-cell transcriptomic work mapping GLP-1 receptor expression in human brain tissue. The receptor is far more restricted in the human CNS than r…
Takeaway
Rodent CNS receptor maps do not transfer cleanly to humans, which weakens a common bridge between animal behavioural results and human claims.
A systematic scoping review counting roughly 180 published animal studies, of which the overwhelming majority originate from a small number of affiliated research groups. Effect si…
Takeaway
The preclinical literature is large but narrow. Consistency within one research network is not the same thing as replication.
Bench work measuring degradation of several model peptides across temperature and humidity conditions chosen to resemble domestic rather than laboratory storage. Deamidation and ox…
Takeaway
Storage conditions can change what is actually in a vial more than most discussions assume. Reported results without storage details are hard to interpret.
How moderation works here
A community about a contested subject only stays useful if disagreement is safe and enforcement is legible. So the rules are narrow, written down, and applied in the open.
There is no hidden state where your posts exist for you and nobody else. If your content is removed, you are told, the community sees a tombstone in its place, and the reason is written out.
Removals, warnings and suspensions all cite a numbered rule from the public rules page. If a moderator cannot name the rule, they cannot take the action. The database requires it.
Any action can be appealed. Appeals are decided by someone other than the moderator who acted, and the decision comes back in writing.
Every public moderation action, its reason, and the outcome of any appeal sits on one page that anyone can read, including people who are not members.
What we remove, without much patience
Everything else, including hard criticism of the moderators, the science, the industry, or this site, is fair game.
Before you join
Browse the guides, skim the rules, and read the public moderation log. All three are open without an account. If how this place is run makes sense to you, the door is right here.
Cancel any time from your account page. No retention calls, no dark patterns.
